Blue Jet Healthcare reported a net profit of ₹64.3 crore for the March quarter, representing a 41.5% decline from ₹110 crore in the corresponding quarter last year. According to reports from CNBC TV18, revenue from operations declined 31% year-on-year to ₹235 crore from ₹340 crore earlier. The company's profit before tax stood at ₹87.1 crore compared to ₹147.2 crore in the year-ago period, while total expenses declined to ₹170.4 crore from ₹205.4 crore. EBITDA fell 49% to ₹71 crore from ₹140 crore a year ago, with EBITDA margin contracting sharply to 30.3% from 41%. Chairman and Managing Director Deepak Gupta noted that the year was marked by a challenging global environment due to the Russia-Ukraine conflict and later emergence of the West Asia crisis, but the company delivered resilient operational and financial performance supported by government policy interventions.
For FY26, Blue Jet Healthcare reported revenue from operations of ₹947.3 crore compared to ₹1,030 crore in FY25, while annual net profit fell to ₹247.8 crore from ₹305.2 crore a year ago. As reported by CNBC TV18, EBITDA for FY26 stood at ₹332.5 crore against ₹406.1 crore in FY25. The board recommended a final dividend of ₹1.2 per equity share of face value ₹2 each for FY26, subject to shareholder approval.
Separately, the company's board approved a proposal to raise up to ₹1,000 crore through qualified institutional placements (QIP), preferential issue, private placement or other permissible routes, subject to shareholder and regulatory approvals. According to reports from CNBC TV18, Blue Jet Healthcare will hold an extraordinary general meeting on June 17, 2026, to seek shareholder approval for the proposed fundraise. The company's shares are now trading 6.8% higher having gained as much as 10% at ₹471.8, though the stock is still down 11% so far in 2026.
